Prostate Cancer - Results from #980

Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis. April 26, 2024

Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer. April 26, 2024

Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals. April 26, 2024

AZGP1 deficiency promotes angiogenesis in prostate cancer. April 26, 2024

Part I: prostate cancer detection, artificial intelligence for prostate cancer and how we measure diagnostic performance: a comprehensive review. April 26, 2024

Ultrasensitive PSA: rethinking post-surgical management for node positive prostate cancer. April 26, 2024

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease. April 26, 2024

Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery. April 26, 2024

Astellas’ XTANDI (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting April 25, 2024

The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities. April 25, 2024

Prostate cancer knowledge and barriers to screening among men at risk in northern Tanzania: A community-based study. April 25, 2024

FOXA1 regulates ribosomal RNA transcription in prostate cancer. April 25, 2024

Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial. April 25, 2024

Reducing False-Positives Due to Urinary Stagnation in the Prostatic Urethra on 18F-DCFPyL PSMA PET/CT With MRI. April 25, 2024

Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up. April 25, 2024

Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations. April 25, 2024

Patient Preference of Apalutamide Versus Enzalutamide for Recurrent or Metastatic Hormone-sensitive Prostate Cancer: An Open-label, Randomized, Crossover Trial. April 25, 2024

Androgen Receptor and Estrogen Receptor Variants in Prostate and Breast Cancers. April 25, 2024

Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. April 25, 2024

Identification of genes that promote PI3K pathway activation and prostate tumour formation. April 25, 2024

Page 50 of 1436